Get the Stockscreener App
76.22
9.04%
6.32
After Hours:
76.00
-0.22
-0.29%
Palvella Therapeutics Inc stock is traded at $76.22, with a volume of 204.93K.
It is up +9.04% in the last 24 hours and up +34.10% over the past month.
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.
See More
Previous Close:
$69.90
Open:
$69.94
24h Volume:
204.93K
Relative Volume:
1.22
Market Cap:
$842.97M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+12.17%
1M Performance:
+34.10%
6M Performance:
+250.28%
1Y Performance:
+0.00%
1-Day Range:
$66.58
$76.76
1-Week Range:
$65.93
$76.76
52-Week Range:
$11.17
$76.76
Palvella Therapeutics Inc Stock (PVLA) Company Profile
Name
Palvella Therapeutics Inc
Sector
Industry
Phone
(484) 253-1461
Address
125 STRAFFORD AVE, WAYNE
Compare PVLA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PVLA
Palvella Therapeutics Inc
|
76.22 | 773.07M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Palvella Therapeutics Inc Stock (PVLA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-09-25 | Initiated | Oppenheimer | Outperform |
| Aug-06-25 | Initiated | Raymond James | Outperform |
| Jul-21-25 | Initiated | Truist | Buy |
| Apr-09-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-26-25 | Initiated | Stifel | Buy |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Feb-20-25 | Initiated | Canaccord Genuity | Buy |
| Feb-05-25 | Initiated | TD Cowen | Buy |
| Dec-26-24 | Initiated | H.C. Wainwright | Buy |
| Dec-18-24 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-13-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jul-30-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-14-19 | Initiated | Robert W. Baird | Outperform |
| Mar-19-18 | Initiated | Evercore ISI | Outperform |
| Mar-19-18 | Initiated | Jefferies | Buy |
| Jan-16-18 | Reiterated | H.C. Wainwright | Buy |
| May-30-17 | Initiated | Rodman & Renshaw | Buy |
| Aug-05-16 | Resumed | ROTH Capital | Buy |
| Aug-12-15 | Initiated | JMP Securities | Mkt Outperform |
| Jul-27-15 | Initiated | Oppenheimer | Outperform |
| Jul-22-15 | Initiated | ROTH Capital | Buy |
View All
Palvella Therapeutics Inc Stock (PVLA) Latest News
Can Palvella Therapeutics Inc. stock withstand economic slowdownBuy Signal & Accurate Entry/Exit Alerts - newser.com
Palvella Receives Second Year of FDA Grant Funding for Phase 3 Qtorin Trial - MarketScreener
What Fibonacci levels say about Palvella Therapeutics Inc. reboundWall Street Watch & Free Community Supported Trade Ideas - newser.com
Can Palvella Therapeutics Inc. stock rebound after recent weaknessProfit Target & Daily Technical Stock Forecast Reports - newser.com
U.S. FDA awards year two funds to Palvella's phase 3 Selva trial - MarketScreener
U.S. Food and Drug Administration Awards Year Two Proceeds from Orphan Products Grant Supporting Palvella Therapeutics’ Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations - Yahoo Finance
Can Palvella Therapeutics Inc. rally from current levelsJuly 2025 Opening Moves & Daily Momentum Trading Reports - newser.com
Palvella Therapeutics (NASDAQ:PVLA) Shares Down 5.9%What's Next? - MarketBeat
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Is Palvella Therapeutics Inc. reversing from oversold territoryJuly 2025 Big Picture & AI Enhanced Trading Alerts - newser.com
Palvella Therapeutics' (PVLA) Sell (D-) Rating Reaffirmed at Weiss Ratings - MarketBeat
Is Palvella Therapeutics Inc. meeting your algorithmic filter criteriaChart Signals & Long-Term Investment Growth Plans - newser.com
Canaccord Genuity raises Palvella Therapeutics stock price target to $90 on new indication - Investing.com Canada
Canaccord Genuity Maintains Palvella Therapeutics (PVLA) Buy Recommendation - Nasdaq
Can trapped investors hope for a rebound in Palvella Therapeutics Inc.Quarterly Profit Review & Risk Adjusted Buy and Sell Alerts - newser.com
Applying big data sentiment scoring on Palvella Therapeutics Inc.Swing Trade & Weekly Top Performers Watchlists - newser.com
Palvella Therapeutics Expands Phase 3 Trial to Younger Patients - MSN
Palvella Therapeutics and Pieris Pharmaceuticals Finalize Merger to Focus on Rare Disease Treatments - MSN
Palvella Therapeutics Names David W. Osborne, Ph.D. as Chief Innovation Officer - MSN
Palvella Therapeutics (NASDAQ:PVLA) Trading 6.6% HigherHere's What Happened - MarketBeat
Palvella Therapeutics (NASDAQ:PVLA) Hits New 1-Year HighHere's Why - MarketBeat
Tick level data insight on Palvella Therapeutics Inc. volatilityMarket Rally & AI Driven Price Predictions - newser.com
Can Palvella Therapeutics Inc. (PI6) stock deliver consistent EPS growthMarket Weekly Review & AI Powered Buy/Sell Recommendations - newser.com
How to interpret RSI for Palvella Therapeutics Inc. stock2025 Price Targets & Long-Term Capital Growth Strategies - newser.com
How to build a custom watchlist for Palvella Therapeutics Inc.Earnings Overview Report & Safe Investment Capital Preservation Plans - newser.com
Will Palvella Therapeutics Inc. bounce back from current supportTrade Analysis Summary & Detailed Earnings Play Alerts - newser.com
LifeSci Capital Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $90 - 富途牛牛
Strid Group LLC Lowers Stake in Palvella Therapeutics, Inc. $PVLA - MarketBeat
Will Palvella Therapeutics Inc. (PI6) stock beat Nasdaq index returnsWeekly Gains Summary & Step-by-Step Swing Trade Plans - newser.com
Truist Financial Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Announces Target Price $80 - 富途牛牛
Published on: 2025-10-03 02:03:51 - newser.com
Truist Securities Maintains Palvella Therapeutics (PVLA) Buy Recommendation - Nasdaq
Palvella Therapeutics (NASDAQ:PVLA) Price Target Raised to $80.00 - MarketBeat
Palvella Completes Phase 2 Trial of QTORIN Rapamycin for Cutaneous Venous Malformations - MSN
Can Palvella Therapeutics Inc. (PI6) stock attract ESG investments2025 Biggest Moves & Community Trade Idea Sharing Platform - newser.com
Is Palvella Therapeutics (NASDAQ:PVLA) A Risky Investment? - 富途牛牛
Palvella Therapeutics Kicks Off Phase 2 Trial for Promising Cutaneous VM Treatment - MSN
Palvella Therapeutics (NASDAQ:PVLA) Hits New 1-Year High Following Analyst Upgrade - Defense World
Palvella Therapeutics (NASDAQ:PVLA) Sets New 52-Week High After Analyst Upgrade - MarketBeat
Palvella Therapeutics Inc Stock (PVLA) Financials Data
There is no financial data for Palvella Therapeutics Inc (PVLA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Palvella Therapeutics Inc Stock (PVLA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| JENKINS GEORGE M | Director |
Apr 09 '25 |
Buy |
20.13 |
2,500 |
50,325 |
183,171 |
| JENKINS GEORGE M | Director |
Dec 18 '24 |
Buy |
12.93 |
4,000 |
51,720 |
180,671 |
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):